OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
ELEV Elevation Oncology
- 0.248
- -0.012-4.48%
Close Apr 1 16:00 ET
- 0.250
- +0.003+1.09%
Post 17:49 ET
14.66MMarket Cap-0.32P/E (TTM)
0.264High0.241Low834.51KVolume0.258Open0.259Pre Close210.73KTurnover2.25%Turnover RatioLossP/E (Static)59.22MShares4.98052wk High0.24P/B9.16MFloat Cap0.24152wk Low--Dividend TTM37.02MShs Float16.220Historical High--Div YieldTTM8.76%Amplitude0.241Historical Low0.252Avg Price1Lot Size
Elevation Oncology Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 35.27%-36.36M | 16.25%-10.2M | 37.25%-8.38M | 40.59%-8.21M | 43.11%-9.58M | 34.28%-56.18M | 31.76%-12.18M | 69.77%-13.36M | -46.50%-13.81M | -20.02%-16.83M |
| Net income from continuing operations | 2.67%-44.49M | -32.12%-10.44M | -21.11%-12.88M | -3.47%-10.46M | 37.24%-10.71M | 51.93%-45.7M | 58.52%-7.9M | 72.61%-10.64M | 49.26%-10.11M | 1.25%-17.06M |
| Operating gains losses | --942K | --0 | --0 | --0 | --942K | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -38.46%24K | -50.00%5K | -44.44%5K | -60.00%4K | 0.00%10K | 44.44%39K | 0.00%10K | 12.50%9K | 100.00%10K | 150.00%10K |
| Other non cash items | -30.77%486K | -38.92%113K | -41.67%105K | -37.79%107K | -2.42%161K | 146.32%702K | 10.78%185K | --180K | --172K | --165K |
| Change In working capital | 128.04%3.84M | 84.22%-675K | 203.52%3.67M | 131.38%1.45M | 51.91%-605K | -317.65%-13.69M | -1,380.84%-4.28M | 43.76%-3.55M | -147.67%-4.61M | -148.25%-1.26M |
| -Change in prepaid assets | 264.12%3.52M | 196.44%786K | 118.57%509K | 94.53%996K | 36.07%1.23M | -251.31%-2.14M | -215.89%-815K | -18.40%-2.74M | -48.95%512K | -6.15%901K |
| -Change in payables and accrued expense | 102.79%322K | 57.81%-1.46M | 491.71%3.17M | 108.77%449K | 15.19%-1.83M | -267.35%-11.55M | -684.97%-3.46M | 79.78%-808K | -159.11%-5.12M | -231.09%-2.16M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 35.27%-36.36M | 16.25%-10.2M | 37.25%-8.38M | 40.59%-8.21M | 43.11%-9.58M | 34.28%-56.18M | 31.76%-12.18M | 69.77%-13.36M | -46.50%-13.81M | -20.02%-16.83M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -172.47%-8.37M | 74.82%11.47M | 92.46%-2.87M | -328.24%-37.66M | -22.18%20.7M | 126.00%11.54M | -41.33%6.56M | -385.18%-38.12M | 59.79%16.5M | 133.56%26.6M |
| Net investment purchase and sale | -172.47%-8.37M | 74.82%11.47M | 92.46%-2.87M | -328.24%-37.66M | -22.18%20.7M | 126.05%11.54M | -41.33%6.56M | -383.36%-38.12M | 59.79%16.5M | 133.56%26.6M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -172.47%-8.37M | 74.82%11.47M | 92.46%-2.87M | -328.24%-37.66M | -22.18%20.7M | 126.00%11.54M | -41.33%6.56M | -385.18%-38.12M | 59.79%16.5M | 133.56%26.6M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -6.33%44.94M | -100.00%-4K | -62.96%10K | -69.24%14.68M | 13,904.63%30.25M | 62.55%47.98M | 50.00%-2K | -99.91%27K | 191,036.00%47.73M | 1,036.84%216K |
| Net common stock issuance | -4.99%44.16M | -100.00%-4K | 33.33%-2K | -68.74%14.54M | 247,016.67%29.63M | 132,897.14%46.48M | 50.00%-2K | 50.00%-3K | 186,084.00%46.5M | ---12K |
| Proceeds from stock option exercised by employees | -36.56%949K | --0 | -60.00%12K | -86.51%167K | 237.72%770K | 7,773.68%1.5M | --0 | --30K | --1.24M | 1,100.00%228K |
| Net other financing activities | ---170K | --0 | --0 | ---20K | ---150K | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -6.33%44.94M | -100.00%-4K | -62.96%10K | -69.24%14.68M | 13,904.63%30.25M | 62.55%47.98M | 50.00%-2K | -99.91%27K | 191,036.00%47.73M | 1,036.84%216K |
| Net cash flow | ||||||||||
| Beginning cash position | 7.27%49.26M | -12.17%48.2M | -44.09%59.45M | 62.12%90.63M | 7.27%49.26M | -68.61%45.92M | 4.35%54.88M | 97.33%106.33M | 5.46%55.9M | -68.61%45.92M |
| Current changes in cash | -93.74%209K | 122.44%1.26M | 78.14%-11.25M | -161.84%-31.18M | 314.37%41.38M | 103.33%3.34M | 15.72%-5.62M | -3,878.89%-51.45M | 5,669.22%50.42M | 110.70%9.99M |
| End cash Position | 0.42%49.46M | 0.42%49.46M | -12.17%48.2M | -44.09%59.45M | 62.12%90.63M | 7.27%49.26M | 7.27%49.26M | 4.35%54.88M | 97.33%106.33M | 5.46%55.9M |
| Free cash flow | 35.27%-36.36M | 16.25%-10.2M | 37.25%-8.38M | 40.59%-8.21M | 43.11%-9.58M | 34.35%-56.18M | 31.76%-12.18M | 69.83%-13.36M | -46.50%-13.81M | -20.02%-16.83M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025